Macrogenics (NASDAQ:MGNX) slips 14% premarket, albeit on only 620 shares, on the heels of updated survival data from a Phase 3 clinical trial evaluating margetuximab in patients with HER2-positive breast cancer.
The combination of the HER2-targeting monoclonal antibody and chemo showed a median increase
in overall survival (OS) of 1.8 months (21.6 months vs. 19.8 months)
compared to the combination of Roche’s Herceptin + chemo with 11.5% less
risk of death (hazard ratio = 0.885). The confidence interval for the
hazard ratio, however, was 0.693 – 1.130 with a p value of 0.326,
meaning, basically, that treatment with margetuximab may not have
improved survival at all.
https://seekingalpha.com/news/3508347-macrogenics-14-percent-premarket-doubts-margetuximab-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.